Welcome to our dedicated page for TTRX news (Ticker: TTRX), a resource for investors and traders seeking the latest updates and insights on TTRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TTRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TTRX's position in the market.
Turn Therapeutics (NASDAQ:TTRX) announced its common stock will commence trading today, October 8, 2025, on the Nasdaq Capital Market under the ticker TTRX.
The company's Form S-1 was declared effective by the SEC on September 30, 2025. Founder and CEO Bradley Burnam will participate in a Closing Bell ceremony at 4:00 PM ET on October 8, 2025, broadcast live from Nasdaq MarketSite. Financial advisor and legal counsel were named: Clear Street LLC (financial advisor) and Davis Polk and Wardwell (legal counsel).
